Abstract template

Guidelines for paper submission

Authors are recommended to follow the format below.

Abstract template

**Title:** A title with the first word and proper nouns capitalized.

< Centered bold, Time New Roman 14, Single space >

**Authors:** Full names (given name, middle initial, family name) of all authors.

< Centered bold, Time New Roman 12, Single space >

**Institutions:** Institution name, province/state, and country. The institutions of the authors with location denoted with a number (1, 2, and 3) behind the author’s last name.

< Centered italic, Time New Roman 12, Single space >

**Corresponding authors:** An email address of corresponding author

(Left, Time New Roman 12, Single space)

**Abstract**

< Left bold, Time New Roman 12, Single space >

**Body of Abstract**

An abstract with a single paragraph of no more than 300 words that should state important objectives, methods, results and principal conclusions of the study. Abbreviations are defined at first use.

< Justify, Time New Roman 12, Single space >

**Keywords:** List up to 5 words in alphabetical order and separated by a comma. Capitalize only proper nouns. Do NOT use abbreviations.

< Justified Italic, Time New Roman 12, Single space >

**Sample abstract**

**Preparation study and bioavailability evaluation of tablets containing fenofibrate nanoparticles**

Hoang Anh Dao 1,2, Nhung Thi Hong Doan 2, Anh Thi Nguyen 2, Liem Duc Ngo 3, Giang Thi Le 2, Giap Thien Le 2 and Chien Ngoc Nguyen 2\*

*1National Institute of Medicinal Materials, Ha Noi, Vietnam*

*2Hanoi University of Pharmacy, Ha Noi, Vietnam*

*3National Institute of Drug Quality Control, Ha Noi, Vietnam*

\*Corresponding authors: chiennn@hup.edu.vn

**Abstract**

The Fenofibrate tablet used was a high-tech dosage form, containing fenofibrate nanoparticles. Its advantage was ahigh bioavailability that was not affected by meal. This study aimed to prepare tablets containing fenofibrate nanoparticles with the same dose and bioavailability as the reference drug (Lipanthyl 145). The study developed a formula of nano fenofibrate suspension including fenofibrate 1,5g, HPC 0,05g, HPMC E6 0,025g, water 5g by wet ball milling. The suspension had a size less than 500nm and the ratio of fenofibrate was nano-sized to 70% after centrifuging at 100 rcf. Fenofibrate granules were made by fluid-bed granulation from milling suspension and fabricated tablet containing 145 mg of fenofibrate. The tablet had dissolution similar to the reference drug. The oral bioavailability of the studied tablets was compared to the reference drug in drugs according to the model of double crossover principle, two doses, two drugs, two periods, two sequences. The results of AUClast (µg\*h/mL), Cmax (µg/mL), Tmax (h) of the studied tablet and reference drug were (45.473; 5.899; 2.625) and (46.019; 5.814; 2.583) respectively. This result showed that preparing nano fenofibrate-containing dosage form equivalent to the reference drug was feasible.

***Keywords:****Ball milling, bioavailability, lipanthyl 145, nano fenofibrate*